The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.
 
Van K. Morris
Honoraria - Projects in Knowledge
Consulting or Advisory Role - Array Biopharma; Incyte; SERVIER
Research Funding - Array BioPharma (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); EMD Serono (Inst)
 
Michael Lam
No Relationships to Disclose
 
Xuemei Wang
No Relationships to Disclose
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Benny Johnson
No Relationships to Disclose
 
Bryan K. Kee
Stock and Other Ownership Interests - Medtronic
 
Robert A. Wolff
Honoraria - Modern Medicine
Patents, Royalties, Other Intellectual Property - Royalties from McGraw-Hill: Editor: M.D. Anderson Manual of Medical Oncology, 3rd edition.
 
Arvind Dasari
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Lexicon; Novartis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Ipsen; Merck; Novartis
 
Isabel R. Zorrilla
No Relationships to Disclose
 
Alda Tam
Honoraria - Endocare
Consulting or Advisory Role - Boston Scientific
Research Funding - BTG
Travel, Accommodations, Expenses - Guerbet
 
Dipen M. Maru
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca/MedImmune; Bayer Health; Biocartis; Boehringer Ingelheim; Boston Biomedical; Daiichi Sankyo; EMD Serono; EMD Serono; Genentech; HalioDx; Holy Stone Healthcare; Ipsen; Jacobio; Karyopharm Therapeutics; Lilly; Lutris; Merck; Natera; Navire; Novartis; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)